Tetrahydropyrazolopyridinones as a Novel Class of Potent and Highly Selective LIMK Inhibitors
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c00974 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Alex G Baldwin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, United Kingdom. Hauptthemen laut MEDLINE: Lim Kinases, Protein Kinase Inhibitors, Pyrazoles, Pyridones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
LIMKs are serine/threonine and tyrosine kinases that play critical roles in regulating actin filament turnover, affecting key cellular processes such as cytoskeletal remodeling, proliferation and migration. Aberrant LIMK overactivation has been implicated in several diseases, including cancers and neurodegenerative disorders. Understanding the precise molecular mechanisms by which LIMKs modulate actin cytoskeletal dynamics necessitates highly potent and selective LIMK pharmacological inhibitors. We report the discovery of a novel class of allosteric dual-LIMK1/2 inhibitors based on the tetrahydropyrazolopyridinone scaffold. Using structure-based drug design, we identified MDI-117740 (69) as a highly potent dual-LIMK1/2 inhibitor with significantly improved DMPK properties compared to prior inhibitors, suitable for in vivo evaluation. Importantly, 69 has very low kinome promiscuity, including former off-target RIPK1, representing the most selective LIMK inhibitor reported to date. Such a chemical probe will enable researchers to selectively dissect LIMK activation under physiological or disease conditions and spur translation of new therapeutics targeting LIMK pathologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, United Kingdom.
- Centre for Medicines Discovery, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, United Kingdom.
- School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, United Kingdom.
ORCID-Profile: Alex G Baldwin, Gui Jie Feng, Benson M Kariuki, Jonathan M Elkins, Simon E Ward
Förderung
- Medical Research Council
Zitieren
APA
Baldwin, A. G., Foley, D. W., Jones, D. H., Lee, H., Collins, R., Wahab, B., Pedder, J. H., Waters, L., Paine, M., Schino, L., Feng, G. J., Kariuki, B. M., Elkins, J. M., Atack, J. R., & Ward, S. E. (2025). Tetrahydropyrazolopyridinones as a Novel Class of Potent and Highly Selective LIMK Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00974
Vancouver
Baldwin AG, Foley DW, Jones DH, Lee H, Collins R, Wahab B, et al. Tetrahydropyrazolopyridinones as a Novel Class of Potent and Highly Selective LIMK Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00974
BibTeX
@article{Baldwin2025,
author = {Baldwin, Alex G and Foley, David W and Jones, D Heulyn and Lee, Hyunah and Collins, Ross and Wahab, Ben and Pedder, Josephine H and Waters, Loren and Paine, Marie and Schino, Lauramariú and Feng, Gui Jie and Kariuki, Benson M and Elkins, Jonathan M and Atack, John R and Ward, Simon E},
title = {Tetrahydropyrazolopyridinones as a Novel Class of Potent and Highly Selective LIMK Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c00974}
}
EUVIMED